实用肿瘤杂志2025，Vol.40Issue(4)：293-305,13.DOI:10.13267/j.cnki.syzlzz.2025.046
肺癌诊治新进展
New progress in diagnosis and treatment of lung cancer
摘要
Abstract
This review summarizes recent clinical progress in the field of lung cancer within the multidisciplinary team(MDT)diagnosis and treatment model across domestic and international studies.In the perioperative treatment of early-stage resectable non-small-cell lung cancer(NSCLC),the"sandwich"strategy combining preoperative neoadjuvant therapy with postoperative adjuvant therapy has demonstrat-ed significant survival benefits for patients.Notably,domestic toripalimab combined chemotherapy significantly increases the major patho-logic response(MPR)rate and event-free survival(EFS)rate of resectable stage Ⅲ NSCLC patients,emerging as a novel treatment regimen for perioperative NSCLC.For unresctable NSCLC patients,consolidative therapy combined with osimertinib,a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor,following radical chemotherapy has significantly extended progression free survival,filling the gap in targeted therapy for stage Ⅲ lung cancer.Furthermore,the combination of immunotherapy and anti-angiogenic agents has ef-fectively improved the overall survival of advanced NSCLC patients.Significant progress has also been made in the field of antibody-drug conjugates,with agents such as sacituzumab and trastuzumab demonstrating substantial therapeutic efficacy.In the field of extensive-stage small-cell lung cancer(ES-SCLC),the bispecific antibody tarlatamab targeting Delta-like ligand 3(DLL3)and cluster of differentiation 3(CD3)has exhibited significant efficacy,and has received accelerated approval from U.S.Food and Drug Administration(FDA)as a sec-ond-line treatment for ES-SCLC.关键词
肺癌/多学科团队/免疫治疗/靶向治疗Key words
lung cancer/multidisciplinary team/immunotherapy/targeted therapy引用本文复制引用
龙贞莉,杨莹,虞永峰,陆舜..肺癌诊治新进展[J].实用肿瘤杂志,2025,40(4):293-305,13.基金项目
国家自然科学基金重点项目(82030045) （82030045）
国家自然科学基金青年基金资助项目(82202924) （82202924）
